PMID- 33177814
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1177-889X (Print)
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 14
DP  - 2020
TI  - Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens 
      for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: 
      Discrete Choice Experiment and Best-Worst Scaling.
PG  - 2201-2214
LID - 10.2147/PPA.S254934 [doi]
AB  - PURPOSE: To understand and compare preferences for dosing- and toxicity-related 
      attributes associated with selective cyclin-dependent 4/6 kinase inhibitors 
      regimens among US oncologists and patients. MATERIALS AND METHODS: Oncologists 
      and patients with mBC participated in an internet-based survey that included a 
      discrete choice experiment (DCE) and a best-worst scaling (BWS) exercise. For the 
      DCE, participants chose between two hypothetical treatment profiles, each with 
      seven attributes: risk of dose reduction due to adverse events (AEs), risk of 
      diarrhea, risk of abdominal pain, need for electrocardiogram (ECG) monitoring to 
      assess heart function, risk of Grade 3/4 neutropenia, dosing regimen, and dosing 
      schedule. The BWS exercise assessed the relative prioritization of a larger set 
      of 16 attributes. Hierarchical Bayesian models were used to estimate preference 
      weights for each attribute level. RESULTS: Oncologists (N=209) and patients 
      (N=304) rated risks of diarrhea (25% each) and Grade 3/4 neutropenia (20% and 
      24%, respectively) as the most important attributes for treatment choice. The 
      risks of diarrhea and Grade 3/4 neutropenia were 1.8 to 2.3 times (oncologists: 
      25% and 20%, respectively vs 11%) and 2.4 to 2.5 times (patients: 25% and 24%, 
      respectively vs 10%) higher in relative importance than the risk of dose 
      reduction due to AEs. Oncologists placed greater importance on the risk of dose 
      reduction due to AEs and the need for ECG monitoring, whereas patients placed 
      greater importance on the risk of Grade 3/4 neutropenia (all, p<0.05). The BWS 
      exercise results were largely consistent with those from the DCE. CONCLUSION: The 
      risks of diarrhea and Grade 3/4 neutropenia were key drivers of both oncologist 
      and patient preferences. Overall, the palbociclib + aromatase inhibitor (AI) 
      profile was most preferred, due to its association with a lower risk of diarrhea 
      and no ECG monitoring, compared with abemaciclib + AI and ribociclib + AI 
      profiles, respectively.
CI  - (c) 2020 Maculaitis et al.
FAU - Maculaitis, Martine C
AU  - Maculaitis MC
AD  - Kantar, Health Division, New York, NY, USA.
FAU - Liu, Xianchen
AU  - Liu X
AUID- ORCID: 0000-0002-4325-2545
AD  - Pfizer Oncology, Pfizer Inc, New York, NY, USA.
FAU - Will, Oliver
AU  - Will O
AD  - Kantar, Health Division, Horsham, PA, USA.
FAU - Hanson, Madelyn
AU  - Hanson M
AD  - Kantar, Health Division, St. Louis, MO, USA.
FAU - McRoy, Lynn
AU  - McRoy L
AD  - Pfizer Oncology, Pfizer Inc, New York, NY, USA.
FAU - Berk, Alexandra
AU  - Berk A
AD  - Kantar, Health Division, New York, NY, USA.
FAU - Crastnopol, Melissa
AU  - Crastnopol M
AD  - Kantar, Health Division, Horsham, PA, USA.
LA  - eng
PT  - Journal Article
DEP - 20201105
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC7652230
OTO - NOTNLM
OT  - adverse events
OT  - metastatic HR positive/HER2 negative breast cancer
OT  - selective cyclin-dependent 4/6 kinase inhibitors
OT  - stakeholder preferences
OT  - treatment administration
OT  - treatment choice
COIS- Martine C. Maculaitis, Oliver Will, Madelyn Hanson, Alexandra Berk, and Melissa 
      Crastnopol are employees of Kantar, who were paid consultants to Pfizer in 
      connection with the development of this manuscript. Xianchen Liu and Lynn McRoy 
      are employees of Pfizer. The authors report no other conflicts of interest in 
      this work.
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:01
PMCR- 2020/11/05
CRDT- 2020/11/12 05:40
PHST- 2020/03/21 00:00 [received]
PHST- 2020/09/25 00:00 [accepted]
PHST- 2020/11/12 05:40 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:01 [medline]
PHST- 2020/11/05 00:00 [pmc-release]
AID - 254934 [pii]
AID - 10.2147/PPA.S254934 [doi]
PST - epublish
SO  - Patient Prefer Adherence. 2020 Nov 5;14:2201-2214. doi: 10.2147/PPA.S254934. 
      eCollection 2020.